Vol.

No.

April 15, 2022Apr 15, 2022

DOWNLOAD THE PDF

Cover Story

At ODAC without sponsors, FDA highlights safety signals in PI3K inhibitor trials

Why is the April 21 ODAC different from all the other ODACs? At all other ODACs, a commercial sponsor gets to make a case. On April 21, only FDA’s voice will be heard.

In new complaint, DOJ says Memphis Methodist, West Clinic broke anti-kickback, false claims laws

By Paul Goldberg

Conversation with The Cancer Letter Free

Yuliya Nogovitsyna: Evacuating children with cancer from Ukraine “a risky operation” as drivers, suppliers are targeted

By Alice Tracey

Conversation with The Cancer Letter Free

ECO’s Mike Morrissey: Ukraine is a priority of our lifetime in oncology

By Matthew Bin Han Ong

Free In the Archives

Cancer disruptors: Jerome Yates on optimism and the ALGB

Free Trials & Tribulations

Let’s close this safety loophole in cancer care

By Daniel E. Fass, Stuart P. Feldman and Mary Farrell Ajango

In Brief

Lisa Coussens named AACR president

NCCN establishes online resources for Ukrainian cancer patients

Robert Vonderheide re-appointed director of Abramson Cancer Center

Ranna Parekh named chief DEI officer at MD Anderson

Charles Rogers, Razelle Kurzrock, Xue-Zhong Yu named to leadership roles at Medical College of Wisconsin

Cleveland Clinic announces new oncology leadership

Cancer Study Group, Fox Chase establish collaborative patient care effort

Michigan-based Karmanos Cancer Institute expands to Ohio

Funding Opportunities

DoD Melanoma Research Program anticipated funding opportunities for FY22

DoD Prostate Cancer Research Program anticipated funding opportunities for FY22

Clinical Roundup

COVID-19 vaccine breakthroughs in cancer patients on the rise due to omicron

ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

MD Anderson study finds combination immunotherapy treatment effective before lung cancer surgery

MD Anderson study finds REFLECT platform optimizes selection of combination cancer therapies

MD Anderson study finds vitamin E can boost immunotherapy responses by reinvigorating dendritic cells

AURORA study identifies molecular features tied to breast cancer tumor spread

Yale study broadens repertoire of cancer-relevant genes

Duomic platform supports simultaneous single-cell TCR profiling and highly multiplexed functional proteomics

Drugs & Targets

FDA fast tracks targeted breast cancer immunotherapy Bria-IMT

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 41 - November 06, 2026